Haloperidol + Diphenhydramine for Agitation
For adults under 65, the combination of intramuscular haloperidol (5 mg), lorazepam (2 mg), and diphenhydramine (50 mg) remains a widely used and effective regimen for severe agitation, though monotherapy with second-generation antipsychotics should be considered first when feasible. However, for patients 65 years and older, avoid this combination entirely—use low-dose oral quetiapine (50-150 mg) as first-line, or if parenteral therapy is absolutely necessary, use haloperidol 0.5 mg IM alone without benzodiazepines or diphenhydramine 1.
Age-Specific Dosing Guidelines
Adults Under 65 Years
- Haloperidol: 5-10 mg IM, maximum 100 mg/day if required (though rarely needed), not exceeding 400 mg total daily dose 2
- Diphenhydramine: 25-50 mg IM/IV (rate not exceeding 25 mg/min), maximum 400 mg/day 2
- This combination is commonly used in psychiatric emergency settings 3, 4
Adults 65 Years and Older
- Haloperidol alone: Start with 0.5 mg IM/IV—this is the evidence-based dose 5
- Maximum initial dose: Do not exceed 1 mg 6, 5
- Avoid diphenhydramine: The anticholinergic burden increases delirium risk, intraocular pressure, and cognitive impairment 7
- Strongly avoid benzodiazepines: They carry excessive risk (OR 5.25 for adverse events vs haloperidol alone) 1
Critical Evidence for Geriatric Patients
The 2025 JAGS Geriatric Emergency Department Guidelines represent the highest quality, most recent evidence and fundamentally change practice for older adults 1. In their systematic review of 838 older adults:
- 16.8% experienced adverse events with antipsychotic/anxiolytic medications
- Midazolam had 53% adverse event rate—over 5 times higher risk than haloperidol
- Quetiapine was the only medication with lower adverse events than haloperidol (OR 0.27)
- Oral administration had superior safety compared to IM/IV routes
Preferred Algorithm for Severe Agitation
Step 1: Attempt Nonpharmacologic Approaches First
- Person-centered communication
- Sensory therapy
- Environmental modifications
Step 2: If Pharmacologic Intervention Required
For patients <65 years:
- First-line: IM olanzapine 10 mg or IM ziprasidone 10-20 mg (monotherapy) 8
- Second-line: Haloperidol 5 mg + diphenhydramine 50 mg ± lorazepam 2 mg IM 3, 4
For patients ≥65 years:
- First-line: Oral quetiapine 50-150 mg 1, 9
- Second-line (if oral not feasible): Haloperidol 0.5 mg IM alone—no benzodiazepines, no diphenhydramine 1, 5
- Alternative: Olanzapine 5-7.5 mg (oral preferred) 9
Contraindications and Cautions
Absolute Contraindications for the Combination
- QTc prolongation >500 ms: Haloperidol prolongs QTc; diphenhydramine and benzodiazepines compound this risk 7
- Severe respiratory depression risk: The combination potentiates CNS depression 7
Relative Contraindications (Use Alternative)
- Age ≥65 years with dementia: Use quetiapine instead 1, 9
- Parkinson's disease: Use quetiapine as first-line 9
- Congestive heart failure: Avoid this combination 9
- Anticholinergic burden: Diphenhydramine worsens delirium, constipation, urinary retention, cognitive impairment 7
Drug Interactions Requiring Dose Adjustment
Haloperidol levels increase significantly with:
- CYP3A4 inhibitors: Ketoconazole, ritonavir, nefazodone 7
- CYP2D6 inhibitors: Paroxetine, fluoxetine, quinidine, promethazine 7
- Combined inhibitors: Fluoxetine, fluvoxamine—reduce haloperidol dose by 50% 7
Monitoring Parameters
Immediate (Within 2 Hours)
- Respiratory rate and oxygen saturation: Watch for respiratory depression, especially with combination therapy 1, 4
- Blood pressure: Monitor for hypotension (common adverse event) 1
- Level of sedation: Use standardized scale (e.g., BARS score) 4
- Need for repeat dosing: Low-dose haloperidol (≤0.5 mg) in elderly requires repeat dosing no more frequently than higher doses 5
Within 24 Hours
- ECG if risk factors present: QTc prolongation, cardiac history, electrolyte abnormalities 7
- Extrapyramidal symptoms: Dystonia, akathisia, rigidity 7, 6
- Delirium assessment: Particularly in elderly—antipsychotics can paradoxically worsen delirium 1
Ongoing
- Fall risk: Increased with all sedating medications 1
- Cardiac monitoring: If QTc >500 ms or arrhythmia develops, discontinue immediately 7
Common Pitfalls to Avoid
Using "standard" 5 mg haloperidol doses in elderly: This is overdosing—0.5 mg is equally effective with better safety 6, 5
Adding benzodiazepines in elderly patients: The 2025 JAGS guidelines show this dramatically increases adverse events without improving efficacy 1
Combining haloperidol + diphenhydramine in patients with delirium: Diphenhydramine's anticholinergic effects worsen delirium 7
Using IM/IV routes when oral is feasible in elderly: Oral administration has superior safety profile 1
Continuing antipsychotics indefinitely for agitated delirium: Taper within 1 week for delirium, 3-6 months for dementia-related agitation 9
Ignoring medication interactions: SSRIs (especially fluoxetine, paroxetine) significantly increase haloperidol levels 7
Duration of Treatment
- Acute agitation/delirium: Discontinue within 1 week once resolved 9
- Agitated dementia: Attempt taper within 3-6 months to find lowest effective maintenance dose 9
- Do not use prophylactically: Only for active symptoms requiring intervention
Physical Compatibility Note
If combining in one syringe (adults <65 only): Haloperidol + lorazepam + diphenhydramine is physically compatible for up to 4 hours 10. However, this does not change the recommendation against using this combination in elderly patients due to safety concerns.